Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, Piruzeli MLB, Goldman JD, Alatorre-Alexander J, de Cassia Pellegrini R, Estrada V, Som M, Cardoso A, Chakladar S, Crowe B, Reis P, Zhang X, Adams DH, Ely EW; COV-BARRIER Study Group.
. Delamuta LC, et al. Clinics (Sao Paulo). 2021 Sep 6;76:e3032. doi: 10.6061/clinics/2021/e3032. eCollection 2021. Clinics (Sao Paulo). 2021. PMID: 34495081
. Free PMC article. No abstract available.